Merck & Co., Inc. (MRK)
| Market Cap | 307.60B +38.1% |
| Revenue (ttm) | 65.01B +1.3% |
| Net Income | 18.25B +6.6% |
| EPS | 7.28 +8.0% |
| Shares Out | 2.48B |
| PE Ratio | 17.02 |
| Forward PE | 24.15 |
| Dividend | $3.40 (2.75%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | 8,459,909 |
| Open | 123.41 |
| Previous Close | 123.82 |
| Day's Range | 122.63 - 124.84 |
| 52-Week Range | 73.31 - 124.84 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 122.36 (-1.27%) |
| Earnings Date | Feb 3, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $122.36, which is a decrease of -1.27% from the latest price.
News
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the TD Cowen 46th Annual Health Care Conference.
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccin...
Merck creates separate oncology arm ahead of Keytruda patent loss
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. Th...
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.
The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution.
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Harbor Large Cap Value Fund Q4 2025 Portfolio Review
During the fourth quarter, the Harbor Large Cap Value Fund returned 1.26%, underperforming its benchmark, the Russell 1000® Value Index, which returned 3.81%, and underperforming the 2.66% return of t...
Merck: Why Investors Should Remain Bullish Despite Patent Risks
Merck started 2026 on a high note. On February 13, its stock reached a 52-week high of $123.3. One of the key reasons Merck is once again becoming a Wall Street favorite is the 6.8% year-over-year inc...
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons.
Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery
Merck & Co. Inc. (NYSE: MRK) on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence (AI) and advanced analytics in drug discovery.
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
RAHWAY, N.J., & ROCHESTER, Minn.--(BUSINESS WIRE)--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025. KEYTRU...
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium.
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) a...
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
LONDON--(BUSINESS WIRE)--Calla Lily Clinical Care, a women's health-focused medical technology company, and Merck, a leading science and technology company, have entered a strategic collaboration to s...
Merck: The Spike Doesn't Make It Overvalued
Merck has surged more than 50% in six months, underpinned by a robust asset portfolio and strong shareholder return strategy. Keytruda, MRK's top-selling drug, faces a 2028 patent cliff, but ongoing i...
Merck: A Buy For 2026, But The Clock Is Still Ticking
Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a one-t...
From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)
Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Future returns now depend on execution and pipeline delivery, not multiple expansion. Keytruda erosio...
Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum
Merck delivered a strong Q4 double beat, with robust pipeline momentum and a healthy new launch cycle supporting a continued buy rating. MRK raised its price target to $130, reflecting normalized $10 ...
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery
Moderna CEO Stéphane Bancel discusses positive cancer vaccine trial results and the impact GLP-1 drugs on 'Mornings with Maria.' #foxbiusiness #morningswithmaria
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.